
|Articles|June 20, 2019
June 2019 Digital Edition
Advertisement
Pipeline watch: we look closely at drugs in phase 2, phase 3 or recently approved for basal cell carcinoma and melanoma. Plus, treating patients with autism, and the physician's impact on regulations and pay.
Subscribe to Dermatology Times!
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermatologic Effects of Energy and High Protein Drinks
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Top 5 Articles of the Week: December 14-19
4
Sachin M. Shridharani, MD, FACS, Reflects on 2025 Trends and Predicts What’s Next in Aesthetic Dermatology
5

















